BioAge Labs Raises $115 Million in Upsized Public Offering to Advance Metabolic Disease Pipeline
核心洞察
BioAge Labs (搜索) completed an upsized $115 million public offering at $19.50 per share to fund development of metabolic disease therapeutics targeting human aging biology.
The company will use proceeds to advance BGE-102, a brain-penetrant NLRP3 (搜索) inhibitor for cardiovascular and retinal diseases (搜索), with Phase 1 topline data expected in first half of 2026.
BioAge is also developing APJ (搜索) agonists for obesity (搜索) treatment and leveraging its proprietary discovery platform built on human longevity data for additional metabolic aging programs.
BioAge Labs (搜索), Inc. (Nasdaq: BIOA) successfully completed an upsized $115 million public offering on January 21, 2026, positioning the clinical-stage biopharmaceutical company to accelerate development of its metabolic disease pipeline targeting the biology of human aging.
The Emeryville, California-based company priced 5,897,435 shares of common stock at $19.50 per share, with Goldman Sachs (搜索) & Co. LLC, Piper Sandler (搜索), and Citigroup (搜索) serving as joint book-running managers. The offering is expected to close on January 23, 2026, with underwriters holding a 30-day option to purchase an additional 884,615 shares.
Lead Candidate Advances Through Clinical Development
BioAge's lead product candidate, BGE-102, represents a potent, orally available, brain-penetrant small-molecule NLRP3 (搜索) inhibitor being developed for cardiovascular risk and retinal diseases (搜索). The company currently has a Phase 1 SAD/MAD (Single Ascending Dose/Multiple Ascending Dose) trial underway, with topline data including additional MAD cohorts anticipated in the first half of 2026.
The NLRP3 (搜索) inflammasome pathway has emerged as a critical target in metabolic diseases (搜索), with BGE-102's brain-penetrant properties potentially offering advantages in treating conditions where central nervous system involvement plays a role.
Expanding Pipeline Targets Obesity and Metabolic Aging
Beyond BGE-102, BioAge is developing both long-acting injectable and oral small molecule APJ (搜索) agonists specifically for obesity (搜索) treatment. The APJ receptor pathway has gained attention as a potential therapeutic target for metabolic disorders, representing another avenue for the company's aging-focused approach.
The company's broader preclinical programs leverage insights from its proprietary discovery platform built on human longevity data, addressing key pathways involved in metabolic aging. This data-driven approach distinguishes BioAge's strategy in the competitive metabolic disease space.
Strategic Use of Capital
BioAge intends to deploy the net proceeds from the offering, combined with existing cash, cash equivalents, and marketable securities, across multiple strategic priorities. The funding will support research, clinical and process development, and manufacturing of product candidates, including BGE-102 and further development of NLRP3 (搜索) and APJ (搜索) programs. Additional uses include working capital, capital expenditures, debt reduction, and general corporate purposes.
The successful completion of this upsized offering reflects investor confidence in BioAge's approach to targeting metabolic diseases (搜索) through the lens of human aging biology, as the company advances multiple programs through clinical development phases.